AU Patent

AU2021203265B2 — Orodispersible dosage unit containing an estetrol component

Assigned to Estetra SRL · Expires 2023-06-08 · 3y expired

What this patent protects

The present invention is directed towards dry estetrol-containing granules comprising: - 70-95 wt.% of one or more granulation excipients, and 5 - 5-30 wt.% of estetrol particles containing at least 90 wt.% of an estetrol component obtainable by a method comprising the steps o…

USPTO Abstract

The present invention is directed towards dry estetrol-containing granules comprising: - 70-95 wt.% of one or more granulation excipients, and 5 - 5-30 wt.% of estetrol particles containing at least 90 wt.% of an estetrol component obtainable by a method comprising the steps of: - providing estetrol particles containing at least 90 wt.% of the estetrol component and having a volume median diameter of 2 m to 50 m; - mixing the estetrol particles with one or more granulation excipients to produce a 0 granulation mixture; - mixing the granulation mixture with a granulation liquid to produce estetrol-containing granules, said granulation liquid containing at least 60 wt.% of liquid solvent; and - removing liquid solvent from the estetrol-containing granules to produce said dry estetrol containing granules.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021203265B2
Jurisdiction
AU
Classification
Expires
2023-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Estetra SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.